Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Type:
Grant
Filed:
October 30, 2013
Date of Patent:
October 27, 2015
Assignee:
INTRA-CELLULAR THERAPRIES, INC.
Inventors:
Sharon Mates, Allen Fienberg, Lawrence P. Wennogle